dulaglutide vs orforglipron

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Type 2 Diabetespeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: April 2027 · NCT07537088 (registry estimate)

Reported efficacy

Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)

Result source: NCT03495102

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: May 2027 · NCT07613307 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideorforglipron
HbA1c, change-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
Body weight, change (kg)-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
HbA1c below 7%75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
Fasting plasma glucose, change-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
3-point MACE (% with event)12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
—Not posted · NCT05803421

HbA1c, change

dulaglutide
-2.0% vs -1.1%−0.9 vs placebo1.5 mg · wk 28 · n 133NCT04591626
25 other results
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 132 · Phase 3 · primary NCT02597049
  • -1.3% vs -0.5% 1.5 mg · wk 24 · n 130 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 134 · Phase 3 · primary NCT02597049
  • -1.2% vs -0.5% 0.75 mg · wk 24 · n 131 · Phase 3 · primary NCT02597049
  • -1.4% vs -0.7% wk 28 · n 150 · Phase 3 · primary NCT02152371
  • -1.4% vs -0.1% wk 24 · n 215 · Phase 3 · primary NCT01769378
  • -1.2% vs -1.1% 1.5 mg · wk 26 · n 138 · Phase 3 · primary NCT01621178
  • -1.7% vs -1.2% 1.5 mg · wk 26 · n 253 · Phase 3 · primary NCT01648582
  • -1.5% vs -0.9% 1.5 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -1.4% 1.5 mg weekly · wk 26 · n 279 · Phase 3 · primary NCT01624259
  • -1.1% vs -1.1% 0.75 mg · wk 26 · n 149 · Phase 3 · primary NCT01621178
  • -1.3% vs -1.2% 0.75 mg · wk 26 · n 252 · Phase 3 · primary NCT01648582
  • -1.2% vs -0.9% 0.75 mg · wk 26 · n 239 · Phase 3 · primary NCT01644500
  • -1.4% vs -0.9% wk 26 · n 178 · Phase 3 · primary NCT01584232
  • -1% vs 0.5% 1.5 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.5% vs 0.5% 0.75 mg · wk 26 · n 50 · Phase 3 · secondary NCT02963766
  • -0.9% vs -1.7% 1.5 mg · wk 156 · n 6579 · Phase 3 · secondary NCT04255433
  • -1.1% vs -1% 1.5 mg · wk 52 · n 130 · Phase 3 · secondary NCT01621178
  • -1.5% vs -0.9% 1.5 mg · wk 52 · n 253 · Phase 3 · secondary NCT01648582
  • -1.1% vs -1% 0.75 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.0% vs -0.9% 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.4% vs -0.4% 4.5 mg · wk 18 · n 66 · Phase 2 · primary NCT02973100
  • -1.3% vs -0.4% 3.0 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.2% vs -0.4% 1.5 mg · wk 18 · n 73 · Phase 2 · primary NCT02973100
  • -1.4% vs 0.1% wk 16 · n 120 · Phase 4 · primary NCT02750410
orforglipron
-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108

Body weight, change (kg)

dulaglutide
-0.8 vs 0.4−1.2 vs placebo1.5 mg · wk 28 · n 133NCT04591626
18 other results
  • -1.9 vs 0.5 wk 28 · n 150 · Phase 3 · secondary NCT02152371
  • -0.9 vs -0.2 wk 24 · n 212 · Phase 3 · secondary NCT01769378
  • -2.8 vs 1.1 1.5 mg · wk 26 · n 140 · Phase 3 · secondary NCT01621178
  • -1.5 vs 1.0 1.5 mg · wk 26 · n 258 · Phase 3 · secondary NCT01648582
  • -1.5 vs 0.9 1.5 mg · wk 26 · n 222 · Phase 3 · secondary NCT01644500
  • -2.9 vs -3.6 1.5 mg weekly · wk 26 · n 299 · Phase 3 · secondary NCT01624259
  • -2.7 vs 1.6 1.5 mg · wk 52 · n 132 · Phase 3 · secondary NCT01621178
  • -1.1 vs 1.4 1.5 mg · wk 52 · n 258 · Phase 3 · secondary NCT01648582
  • -2.0 vs 1.1 0.75 mg · wk 26 · n 151 · Phase 3 · secondary NCT01621178
  • -0.9 vs 1.0 0.75 mg · wk 26 · n 257 · Phase 3 · secondary NCT01648582
  • -0.8 vs 0.9 0.75 mg · wk 26 · n 224 · Phase 3 · secondary NCT01644500
  • -1.7 vs 1.6 0.75 mg · wk 52 · n 137 · Phase 3 · secondary NCT01621178
  • -0.8 vs 1.4 0.75 mg · wk 52 · n 257 · Phase 3 · secondary NCT01648582
  • -0.5 vs 0.9 wk 26 · n 180 · Phase 3 · secondary NCT01584232
  • -4.1 vs -1.6 4.5 mg · wk 18 · n 67 · Phase 2 · secondary NCT02973100
  • -3.9 vs -1.6 3.0 mg · wk 18 · n 74 · Phase 2 · secondary NCT02973100
  • -2.8 vs -1.6 1.5 mg · wk 18 · n 72 · Phase 2 · secondary NCT02973100
  • -0.2 vs -0.3 wk 16 · n 120 · Phase 4 · secondary NCT02750410
orforglipron
-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719

HbA1c below 7%

dulaglutide
75.9% vs 33.8%+42.1 vs placebo1.5 mg · wk 28 · n 133NCT04591626
8 other results
  • 37.5% vs 34.6% 1.5 mg · wk 26 · n 152 · Phase 3 · secondary NCT01621178
  • 32.9% vs 29.1% 1.5 mg · wk 52 · n 152 · Phase 3 · secondary NCT01621178
  • 31.7% vs 34.6% 0.75 mg · wk 26 · n 164 · Phase 3 · secondary NCT01621178
  • 33.5% vs 29.1% 0.75 mg · wk 52 · n 164 · Phase 3 · secondary NCT01621178
  • 68.2% vs 20% 4.5 mg · wk 18 · n 66 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 3.0 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 71.2% vs 20% 1.5 mg · wk 18 · n 73 · Phase 2 · secondary NCT02973100
  • 0% vs 47.4% wk 16 · n 116 · Phase 4 · secondary NCT02750410
orforglipron
79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719

Fasting plasma glucose, change

dulaglutide
-2.2 vs -2.4vs Insulin Glargine1.5 mg · wk 52 · n 253NCT01648582
3 other results
  • -2.4 vs -2.6 1.5 mg · wk 26 · n 253 · Phase 3 · secondary NCT01648582
  • -1.5 vs -2.4 0.75 mg · wk 52 · n 252 · Phase 3 · secondary NCT01648582
  • -1.7 vs -2.6 0.75 mg · wk 26 · n 252 · Phase 3 · secondary NCT01648582
orforglipron
-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474

3-point MACE (% with event)

dulaglutide
12% vs 13.4%−1.4 vs placebon 4949NCT01394952
1 other result
  • 13.1% vs 12.2% 1.5 mg · wk 259 · n 6579 · Phase 3 · primary NCT04255433
orforglipron
—Not posted · NCT05803421
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. dulaglutide: 11 of 11 rows · orforglipron: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdulaglutide
Rows use multiple source trials
orforglipron
Rows use multiple source trials
Fasting Serum Glucose Change mg/dL
absolute change · mg
-58.47 vs -43.64 placebo mg @ 28wk1.5 mga,b,c
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
-37.8 vs -1.1 placebo mg @ 40wk36 mgd,a,b,c
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more doses
-37.4 vs -1.1 placebo mg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-30.6 vs -1.1 placebo mg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL
absolute change · mg
No placebo or comparator arm
-42.4 mg @ 52wk1.5 mgd,a,b
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-33.1 mg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-64.5 mg @ 52wk36 mgd,a,b
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-55.1 mg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-51.7 mg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.5% (n=383) @ 52wk1.5 mgd,a,b
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.19% (n=193) @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-2.13% (n=125) @ 52wk36 mgd,a,b
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1.97% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.71% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
71.48% (n=526) @ 36wk4.5 mgd,a,b,e
NCT03495102 · Phase 3
show 2 more doses
64.68% (n=521) @ 36wk3 mg
NCT03495102 · Phase 3
56.98% (n=523) @ 36wk1.5 mg
NCT03495102 · Phase 3
90.82% (n=125) @ 52wk36 mgd,a,b,e
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
86.11% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
82.73% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL
absolute change · mg
-64 vs -37.7 placebo mg @ 28wk1.5 mga,b,c
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
-58.1 vs -17.6 placebo mg @ 40wk36 mgd,a,b,c
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more doses
-56 vs -17.6 placebo mg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-43.6 vs -17.6 placebo mg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Weight
percent change · % of baseline
-4.82% (n=6578) vs -11.6% (n=6586) Tirzepatide @ 156wk1.5 mgf,b,g
NCT04255433 · Phase 3 · registry result, not featured evidence
-9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mgf,b,g
NCT05872620 · Phase 3 · sponsor-reported, not registry data
Weight
absolute change · kg
No placebo or comparator arm
-0.5 kg @ 52wk1.5 mgd,a,b
NCT04809220 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.2 kg @ 52wk0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
-6.75 kg @ 52wk36 mgd,a,b
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-5.08 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.81 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Dropout rate
0.3%h
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
4.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.8%4.5 mg
NCT03495102 · Phase 3
10.9%3 mg
NCT03495102 · Phase 3
9.2%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
3.8%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
3.9%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
2.5%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
2.2%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.1%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
4.9%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
3.5%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
8%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
12.4%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
14.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
10.4%
NCT01769378 · Phase 3 · registry result, not featured evidence
9%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
9.7%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
10%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
9.2%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
5.1%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
16.7%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
6.7%36 mgi
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
5.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
5.3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3.5%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
8.8%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
6.3%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
7.4%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
11.8%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.7%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
7.8%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
9.4%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
57.1%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—h
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
1.7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%4.5 mg
NCT03495102 · Phase 3
1.1%3 mg
NCT03495102 · Phase 3
0.8%1.5 mg
NCT03495102 · Phase 3
—1.5 mg
NCT01621178 · Phase 3
—0.75 mg
NCT01621178 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
0%0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
—1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
1.7%Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
—
NCT03315780 · Phase 4 · registry result, not featured evidence
—1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
—1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.4%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
0%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
4%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
2.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.3%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
4.2%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
0.4%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
—1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
6%LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
2.6%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
1.3%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
—
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
—Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
8.3%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
2.2%36 mgi
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
4.4%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.5%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.4%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0.7%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.6%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
35.7%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Serious AEs
40.3%h
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 45 more results
5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.2%4.5 mg
NCT03495102 · Phase 3
7.3%3 mg
NCT03495102 · Phase 3
8.7%1.5 mg
NCT03495102 · Phase 3
21.4%1.5 mg
NCT01621178 · Phase 3
25.3%0.75 mg
NCT01621178 · Phase 3
—1.5 mg
NCT02963766 · Phase 3
1.9%1.5 mg
NCT02963766 · Phase 3
4%1.5 mg
NCT02963766 · Phase 3
—0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
2%0.75 mg
NCT02963766 · Phase 3
0%1.5 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
0%0.75 mg
NCT05659537 · Phase 4 · registry result, not featured evidence
2.5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
5%0.75 mg
NCT02750410 · Phase 4 · registry result, not featured evidence
—Dulaglutide
NCT02750410 · Phase 4 · registry result, not featured evidence
0%
NCT03315780 · Phase 4 · registry result, not featured evidence
31.9%1.5 mg
NCT04255433 · Phase 3 · registry result, not featured evidence
3.8%1.5 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
3.6%0.75 mg
NCT04809220 · Phase 3 · registry result, not featured evidence
5.6%1.5 mg
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
3.5%1.5 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
2.1%0.75 mg
NCT02597049 · Phase 3 · registry result, not featured evidence
6%
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
9.3%1.5 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
5.8%0.75 mg
NCT01648582 · Phase 3 · registry result, not featured evidence
3.8%
NCT01769378 · Phase 3 · registry result, not featured evidence
2.5%1.5 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.6%0.75 mg
NCT01644500 · Phase 3 · registry result, not featured evidence
1.7%1.5 mg weekly
NCT01624259 · Phase 3 · registry result, not featured evidence
—LY2189265
NCT01624259 · Phase 3 · registry result, not featured evidence
3.9%4.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
8.9%3.0 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
3.7%1.5 mg
NCT02973100 · Phase 2 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%1.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.75 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
9.1%0.5 mg
NCT01667900 · Phase 1 · registry result, not featured evidence
0%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide + Warfarin
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
0%Dulaglutide Alone
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
0%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
4.5%36 mgi
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
2.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.8%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.1%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.6%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2.9%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
1.8%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
5.9%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.1%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
h
nausea 14.9% (placebo 5.4%)
diarrhoea 13.5% (placebo 8.8%)
nasopharyngitis 11.4% (placebo 10.8%)
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 41 more results
nasopharyngitis 27.1%
diarrhoea 12.2%
nausea 9.4%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.5 mg
nausea 17.3%
diarrhoea 11.4%
vomiting 10.4%
NCT03495102 · Phase 3
3 mg
nausea 16.1%
diarrhoea 12.2%
vomiting 9.3%
NCT03495102 · Phase 3
1.5 mg
nausea 14.2%
diarrhoea 7.8%
vomiting 6.5%
NCT03495102 · Phase 3
1.5 mg
blood creatinine increased 38.5%
nausea 19.8%
diarrhoea 16.1%
NCT01621178 · Phase 3
0.75 mg
blood creatinine increased 37.4%
diarrhoea 15.8%
nausea 14.2%
NCT01621178 · Phase 3
1.5 mg
diarrhoea 21.2% (placebo 13.7%)
headache 15.4% (placebo 9.8%)
nausea 15.4% (placebo 7.8%)
NCT02963766 · Phase 3
1.5 mg
diarrhoea 12% (placebo 13.7%)
nausea 12% (placebo 7.8%)
abdominal pain upper 10% (placebo 7.8%)
NCT02963766 · Phase 3
0.75 mg
vomiting 17.6% (placebo 3.9%)
diarrhoea 15.7% (placebo 13.7%)
headache 13.7% (placebo 9.8%)
NCT02963766 · Phase 3
0.75 mg
headache 10.2% (placebo 9.8%)
vomiting 8.2% (placebo 3.9%)
abdominal pain 6.1% (placebo 5.9%)
NCT02963766 · Phase 3
1.5 mg
gastritis 14.3%
dyslipidaemia 9.5%
nausea 9.5%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
anaemia 21.4%
gastritis 14.3%
dyslipidaemia 7.1%
NCT05659537 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 15.8% (placebo 30.8%)
abdominal discomfort 8.3% (placebo 12.8%)
constipation 6.7% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
0.75 mg
nasopharyngitis 28.3% (placebo 30.8%)
constipation 10.8% (placebo 12.8%)
abdominal discomfort 9.2% (placebo 12.8%)
NCT02750410 · Phase 4 · registry result, not featured evidence
influenza 16.7% (placebo 0%)
decreased appetite 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 8.3%)
NCT03315780 · Phase 4 · registry result, not featured evidence
1.5 mg
nausea 22.3%
diarrhoea 18.9%
covid-19 15.1%
NCT04255433 · Phase 3 · registry result, not featured evidence
1.5 mg
constipation 12.5%
diarrhoea 10.2%
pyrexia 10%
NCT04809220 · Phase 3 · registry result, not featured evidence
0.75 mg
constipation 8.7%
nasopharyngitis 8.7%
covid-19 8.2%
NCT04809220 · Phase 3 · registry result, not featured evidence
1.5 mg
decreased appetite 22.2% (placebo 4.1%)
diabetic nephropathy 13.9% (placebo 15%)
diarrhoea 13.2% (placebo 8.2%)
NCT04591626 · Phase 3 · registry result, not featured evidence · add on
1.5 mg
nausea 14.8% (placebo 3.6%)
back pain 9.2% (placebo 7.1%)
viral upper respiratory tract infection 6.3% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
0.75 mg
diarrhoea 9.9% (placebo 2.9%)
back pain 8.5% (placebo 7.1%)
viral upper respiratory tract infection 5.7% (placebo 7.9%)
NCT02597049 · Phase 3 · registry result, not featured evidence
nausea 12% (placebo 1.3%)
diarrhoea 11.3% (placebo 4%)
upper respiratory tract infection 7.3% (placebo 6.7%)
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
1.5 mg
hyperlipidaemia 17.8%
diarrhoea 16.7%
lipase increased 10.5%
NCT01648582 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 19.5%
diarrhoea 10.9%
hypertension 10.9%
NCT01648582 · Phase 3 · registry result, not featured evidence
nausea 10.5% (placebo 0%)
diarrhoea 8.4% (placebo 0%)
eructation 5.9% (placebo 0%)
NCT01769378 · Phase 3 · registry result, not featured evidence
1.5 mg
diarrhoea 17.2%
hyperlipidaemia 11.1%
nausea 10.2%
NCT01644500 · Phase 3 · registry result, not featured evidence
0.75 mg
hyperlipidaemia 12.1%
diarrhoea 7.3%
lipase increased 5.6%
NCT01644500 · Phase 3 · registry result, not featured evidence
1.5 mg weekly
nausea 20.4%
diarrhoea 12%
dyspepsia 8%
NCT01624259 · Phase 3 · registry result, not featured evidence
4.5 mg
nausea 30.3% (placebo 4.9%)
diarrhoea 21.1% (placebo 11.1%)
vomiting 13.2% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 25.3% (placebo 4.9%)
diarrhoea 22.8% (placebo 11.1%)
decreased appetite 16.5% (placebo 1.2%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
nausea 22.2% (placebo 4.9%)
diarrhoea 11.1% (placebo 11.1%)
vomiting 11.1% (placebo 4.9%)
NCT02973100 · Phase 2 · registry result, not featured evidence
1.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
blood pressure decreased 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
1.5 mg
abdominal discomfort 10% (placebo 6.3%)
decreased appetite 10% (placebo 0%)
nausea 10% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
abdominal discomfort 9.1% (placebo 6.3%)
nausea 9.1% (placebo 0%)
vomiting 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.75 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal distension 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
abdominal discomfort 0% (placebo 6.3%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
0.5 mg
decreased appetite 18.2% (placebo 0%)
abdominal discomfort 9.1% (placebo 6.3%)
abdominal pain 9.1% (placebo 0%)
NCT01667900 · Phase 1 · registry result, not featured evidence
headache 41.2%
nausea 41.2%
vomiting 35.3%
NCT01458210 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 8%
haemorrhoids 4%
injection site pain 4%
NCT01432938 · Phase 1 · registry result, not featured evidence · combination
vomiting 11.5%
decreased appetite 7.7%
headache 7.7%
NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy
gastrooesophageal reflux disease 33.3%
atrioventricular block first degree 28.6%
headache 28.6%
NCT01436201 · Phase 1 · registry result, not featured evidence · combination
36 mgi
constipation 29.1%
nausea 27.6%
nasopharyngitis 16.4%
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
12 mg
constipation 30.4%
nasopharyngitis 22.2%
nausea 19.3%
NCT06010004 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 17.4%
constipation 16.7%
nausea 12.9%
NCT06010004 · Phase 3 · registry result, not featured evidence
36 mg
diarrhoea 25.5% (placebo 9.4%)
diabetic retinopathy 17% (placebo 15.2%)
nausea 17% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
12 mg
diarrhoea 21.2% (placebo 9.4%)
dyspepsia 21.2% (placebo 7.2%)
nausea 19% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
3 mg
diarrhoea 18.9% (placebo 9.4%)
diabetic retinopathy 14.7% (placebo 15.2%)
nausea 12.6% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
36 mg
nausea 37% (placebo 5.5%)
vomiting 33.3% (placebo 1.8%)
diarrhoea 25.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
36 mg
nausea 26.5% (placebo 5.5%)
vomiting 20.6% (placebo 1.8%)
eructation 8.8% (placebo 0%)
NCT05048719 · Phase 2 · registry result, not featured evidence
12 mg
nausea 37.5% (placebo 5.5%)
vomiting 21.4% (placebo 1.8%)
diarrhoea 16.1% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 23.5% (placebo 5.5%)
diarrhoea 21.6% (placebo 7.3%)
constipation 13.7% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
vomiting 35.5% (placebo 1.8%)
diarrhoea 29% (placebo 7.3%)
nausea 29% (placebo 5.5%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 28.1% (placebo 7.3%)
nausea 25% (placebo 5.5%)
vomiting 21.9% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
24 mg
nausea 34% (placebo 5.5%)
vomiting 27.7% (placebo 1.8%)
diarrhoea 14.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 55.6% (placebo 25%)
constipation 33.3% (placebo 0%)
vomiting 22.2% (placebo 25%)
NCT05086445 · Phase 1 · registry result, not featured evidence
2 mg
vomiting 40% (placebo 25%)
nausea 30% (placebo 25%)
abdominal distension 20% (placebo 0%)
NCT05086445 · Phase 1 · registry result, not featured evidence
3/6/12/15 mg QD
nausea 50% (placebo 5.9%)
vomiting 50% (placebo 0%)
decreased appetite 40% (placebo 11.8%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21 mg QD
nausea 42.9% (placebo 5.9%)
decreased appetite 28.6% (placebo 11.8%)
covid-19 21.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21/27 mg QD
decreased appetite 55.6% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
nausea 33.3% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9 mg QD
vomiting 55.6% (placebo 0%)
decreased appetite 44.4% (placebo 11.8%)
nausea 44.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9/21/36/45 mg QD
nausea 77.8% (placebo 5.9%)
decreased appetite 66.7% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
NCT04426474 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 40 weeks versus 28 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 52 weeks versus 36 weeks.
  6. fPopulation context differs: registered conditions differ.
  7. gAssessment timepoints differ: 72 weeks versus 156 weeks.
  8. hPopulation comparability has not been reviewed for 44 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

dulaglutide

MACE 3-point Composite 13.1% (n=6579) vs 12.2% (n=6586) Tirzepatide @ 259wk1.5 mg
event count · % of participants
NCT04255433 · Phase 3 · registry result, not featured evidence · converted to % from 862 participants as posted
show 1 more result
12% (n=4949) vs 13.4% (n=4952) placebo*
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 594 Participants as posted
Microvascular Composite 22.2% (n=4949) vs 25.1% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 1099 Participants as posted
HF Hospitalization or Urgent Visit 4.3% (n=4949) vs 4.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 213 Participants as posted
Unstable Angina Hospitalization 1.8% (n=4949) vs 1.6% (n=4952) placebo
event count · % of participants
NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 Participants as posted
HbA1c Less Than or Equal to 6.5 51.1% (n=178) vs 24% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <=6.5%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 71.3% (n=178) vs 45.8% (n=179) Insulin Glargine @ 26wk
responder rate · % of participants
HbA1c <7%
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
FBG -34.3 vs -37.8 Insulin Glargine mg @ 26wk
absolute change · mg
NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 8 78.3% (n=152) vs 75.3% (n=182) Insulin Glargine @ 26wk1.5 mg
responder rate · % of participants
NCT01621178 · Phase 3
show 3 more results
69.1% (n=152) vs 70.3% (n=182) Insulin Glargine @ 52wk1.5 mg
NCT01621178 · Phase 3
72.6% (n=164) vs 75.3% (n=182) Insulin Glargine @ 26wk0.75 mg
NCT01621178 · Phase 3
69.5% (n=164) vs 70.3% (n=182) Insulin Glargine @ 52wk0.75 mg
NCT01621178 · Phase 3
SMBG 8-point Change mg/dL -33.7 vs -37.6 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 1 more result
-31.7 vs -37.6 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
Fasting Glucose Change mg/dL 23.1 vs -19.1 Insulin Glargine mg @ 26wk1.5 mg
absolute change · mg
NCT01621178 · Phase 3
show 2 more results
17.7 vs -19.1 Insulin Glargine mg @ 26wk0.75 mg
NCT01621178 · Phase 3
-44.63 vs -27.9 placebo mg @ 28wk
NCT02152371 · Phase 3 · registry result, not featured evidence · combination
Daily Insulin Dose 18.12 vs 16.64 Insulin Glargine per day @ 26wk1.5 mg
absolute change · per day
NCT01621178 · Phase 3
show 4 more results
20.05 vs 16.84 Insulin Glargine per day @ 52wk1.5 mg
NCT01621178 · Phase 3
26.16 vs 16.64 Insulin Glargine per day @ 26wk0.75 mg
NCT01621178 · Phase 3
27.46 vs 16.84 Insulin Glargine per day @ 52wk0.75 mg
NCT01621178 · Phase 3
-1.1 vs -0.3 placebo per day @ 16wk
NCT02750410 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL 0.04 vs 0.1 Insulin Glargine mg/dL @ 26wk1.5 mg
absolute change · mg/dL
NCT01621178 · Phase 3
show 3 more results
0.07 vs 0.12 Insulin Glargine mg/dL @ 52wk1.5 mg
NCT01621178 · Phase 3
0.02 vs 0.1 Insulin Glargine mg/dL @ 26wk0.75 mg
NCT01621178 · Phase 3
0.04 vs 0.12 Insulin Glargine mg/dL @ 52wk0.75 mg
NCT01621178 · Phase 3

+ 54 further endpoints in the CSV export.

orforglipron

HbA1c Less Than or Equal to 6.5 84.56% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
76.23% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
62.64% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 5 7 30.51% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
21.92% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
7.7% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 65.14% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
49.52% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
27% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 10% 37.91% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
24.68% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
10.11% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 15% 20.94% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
13.96% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.79% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -6.5 cm @ 52wk36 mg
absolute change · cm
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-4.6 cm @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-2.4 cm @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
BMI -2.5 kg @ 52wk36 mg
absolute change · kg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-1.9 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-0.7 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -82.27 mg/dL @ 52wk36 mg
absolute change · mg/dL
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-73.14 mg/dL @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-66.32 mg/dL @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 68.91% (n=119) vs 18.56% (n=97) placebo @ 40wk36 mg
responder rate · % of participants
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
68.75% (n=112) vs 18.56% (n=97) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
66.39% (n=119) vs 18.56% (n=97) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Non-HDL-C -7.91% (n=137) vs 3.19% (n=135) placebo @ 40wk36 mg
percent change · % of baseline
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-4.8% (n=131) vs 3.19% (n=135) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-1.82% (n=136) vs 3.19% (n=135) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Triglycerides -14% (n=136) vs 0% (n=135) placebo @ 40wk36 mg
percent change · % of baseline
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-16.5% (n=130) vs 0% (n=135) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-9.1% (n=136) vs 0% (n=135) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 66.39% (n=119) vs 14.58% (n=96) placebo @ 40wk36 mg
responder rate · % of participants
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
58.56% (n=111) vs 14.58% (n=96) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
47.06% (n=119) vs 14.58% (n=96) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

dulaglutide · Trulicity

Marketed by Eli Lilly

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT01394952 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).

Next expected readout: December 2030 · NCT07282041 (registry estimate)

Reported efficacy

Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 (met)

Result source: NCT01394952

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07223593 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdulaglutideorforglipron
LDL-C, % change—Trial running · NCT07282041—Trial running · NCT07241390
Non-HDL-C, % change—Trial running · NCT07282041—Trial running · NCT07241390
ApoB, % change—Trial running · NCT07282041—Trial running · NCT07241390
Lp(a), % change—Trial running · NCT07282041—Trial running · NCT07241390
3-point MACE (% with event)—Trial running · NCT07282041—Trial running · NCT07241390

LDL-C, % change

dulaglutide
—Trial running · NCT07282041
orforglipron
—Trial running · NCT07241390

Non-HDL-C, % change

dulaglutide
—Trial running · NCT07282041
orforglipron
—Trial running · NCT07241390

ApoB, % change

dulaglutide
—Trial running · NCT07282041
orforglipron
—Trial running · NCT07241390

Lp(a), % change

dulaglutide
—Trial running · NCT07282041
orforglipron
—Trial running · NCT07241390

3-point MACE (% with event)

dulaglutide
—Trial running · NCT07282041
orforglipron
—Trial running · NCT07241390
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

orforglipron: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

dulaglutide
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952 NCT01394952 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · orforglipron's landscape